
Third-quarter revenue rose 32%, while the company reduced its full-year revenue and adjusted earnings guidance amid order timing uncertainty and acquisition-related charges.
BioMarin’s third-quarter revenue rose 32% year over year to $1.025 billion, its first quarter above $1 billion, as the company added sales from recently acquired medicines. The biotech also lowered its full-year 2026 revenue and adjusted earnings guidance.
The company now expects full-year revenue of $3,800 million to $3,900 million, compared with its previous range of $3,875 million to $3,925 million. BioMarin cited uncertainty over the timing of multiple orders from one international customer.
BioMarin reported a GAAP net loss of $123 million, compared with a $31 million loss a year earlier. Non-GAAP income increased to $45 million from $22 million.
The company said the GAAP loss reflected costs tied to its Amicus Therapeutics acquisition, including interest expense and intangible asset amortization, as well as acquired research and development charges related to Alesta Therapeutics. Its updated non-GAAP diluted earnings guidance is $2.80 to $3.10 per share, down from $4.90 to $5.10.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.